Bristol Myers Squibb (BMY) Net Income towards Common Stockholders (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Net Income towards Common Stockholders data on file, last reported at $2.7 billion in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $2.7 billion, up 8.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 billion (up 36.58% YoY), and the FY2025 annual result was $7.1 billion, up 178.99% from the prior year.
• Net Income towards Common Stockholders rose to $2.7 billion in Q1 2026 per BMY's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $2.7 billion in Q1 2026 and troughed at -$11.9 billion in Q1 2024.
• A 5-year average of $883.5 million and a median of $1.6 billion in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders sank 625.28% in 2024, then soared 1328.95% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $2.0 billion in 2022, then fell by 15.7% to $1.7 billion in 2023, then plunged by 95.55% to $76.0 million in 2024, then soared by 1328.95% to $1.1 billion in 2025, then soared by 146.69% to $2.7 billion in 2026.
• Business Quant data shows BMY's Net Income towards Common Stockholders at $2.7 billion in Q1 2026, $1.1 billion in Q4 2025, and $2.2 billion in Q3 2025.